Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 29, 2000

View Archived Issues

NeoRx's myeloma therapy shows excellent phase II safety results

La Jolla Pharmaceutical updates progress with lupus drug

Vical, Human Genome Sciences and Vascular Genetics form collaboration

Angiotech announces promising results from phase I/II SPMS study

Unigene achieves milestone in osteoporosis collaboration

Micardis enters large-scale efficacy trial

Oxford GlycoSciences highlights principal achievements for 1999

Medco shareholders approve merger with King Pharmaceuticals

Selective rotamase inhibitors described by Pfizer for neurological disorders

Zambon presents new PDE4 inhibitors useful for respiratory diseases

Hepatitis C product candidate enters phase I testing in U.K.

New cardiovascular/renal agents under study at SmithKline Beecham

Tulane team studies gene therapy for pulmonary hypertension

Bioprojet claims new, orally active histamine H3 antagonists

Wound-healing gene therapy using NAB2

New series from American Cyanamid inhibits angiogenesis by targeting VEGF

Joint effort by OSI, Wyeth-Ayerst results in identification of novel calcitonin-inducing agents

AdProTech's APT-070 shows encouraging preclinical results in transplantation

5-HT2C receptor inverse agonists selected for further study in CNS disorders

Lorus's lead anticancer products reduce tumor growth in mouse models of prostate cancer

Nycomed Amersham receives approvable letter for extended use of Myoview

IRB approval received to commence phase II trial of GBC-590

Abgenix extends antibody collaboration with Pfizer

Searle identifies novel series of LTA4 hydrolase inhibitors, some with good oral activity

Safety and efficacy of seocalcitol examined in phase II colorectal cancer study

Positive early clinical results for decitabine in advanced NSCLC

Monoclonal antibody targeting Lewis X combined with chemotherapy in breast cancer